1. CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. (June 2017) Authors: Nastoupil, L.; Lunning, M.A.; Vose, J.M.; Schreeder, M.T.; Siddiqi, T.; Flowers, C.R.; Cohen, J.B.; Burger, J.A.; Wierda, W.G.; O'Brien, S.; Sportelli, P.; Miskin, H.P.; Purdom, M.A.; Weiss, M.S.; Fowler, N.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗